
-
Theravance Biopharma NASDAQ:TBPH Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to create transformational medicines to improve the lives of patients suffering from serious illnesses. Its research is focused in the areas of inflammation and immunology.
Location: Ugland House, South Church Street, Grand Cayman, KY1-1104, Cayman Islands | Website: www.theravance.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
443.8M
Cash
88.35M
Avg Qtr Burn
-2.884M
Short % of Float
16.19%
Insider Ownership
4.55%
Institutional Own.
91.67%
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
YUPELRI® (revefenacin) Details Chronic obstructive pulmonary disease | Approved Quarterly sales | |
TRELEGY ELLIPTA Details Asthma | Approved Quarterly sales | |
TRELEGY ELLIPTA Details Chronic obstructive pulmonary disease (COPD) | Approved Quarterly sales | |
Ampreloxetine (TD-9855) Details Multiple System Atrophy, Neurogenic orthostatic hypotension | Phase 3 Data readout | |
Izencitinib (TD-1473) (GUT-SELECTIVE JAK INHIBITOR) Details Inflammatory bowel disease, Inflammatory disease, Ulcerative colitis, Crohns disease | Failed Discontinued | |
Izencitinib (TD-1473) (GUT-SELECTIVE JAK INHIBITOR) Details Crohns disease | Failed Discontinued | |
Nezulcitinib (TD-0903) (Janus kinase inhibitor (JAKi)) Details COVID-19, Skin disease/disorder | Failed Discontinued |